
FDA Grants Orphan Drug Exclusivity to Mesoblast's Ryoncil for Pediatric GVHD
The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children ages 2 months and older, the company announced …